Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 2
2018 3
2019 2
2020 1
2021 1
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, McTigue K, Thicklin F, Felker GM, Ginde AA, Bramante CT, Slandzicki AJ, Gabriel A, Shah NS, Lenert LA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Wilder R, Wilson S, Shenkman E, Hernandez AF; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Naggie S, et al. JAMA. 2022 Oct 25;328(16):1595-1603. doi: 10.1001/jama.2022.18590. JAMA. 2022. PMID: 36269852 Free PMC article. Clinical Trial.
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Slandzicki AJ, Lim SC, Cohen J, Kavtaradze D, Amon AP, Gabriel A, Gentile N, Felker GM, Jayaweera D, McCarthy MW, Sulkowski M, Rothman RL, Wilson S, DeLong A, Remaly A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Thicklin F, Hanna GJ, Ginde AA, Castro M, McTigue K, Shenkman E, Hernandez AF; Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Naggie S, et al. JAMA. 2023 Mar 21;329(11):888-897. doi: 10.1001/jama.2023.1650. JAMA. 2023. PMID: 36807465 Free PMC article.
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.
Boulware DR, Lindsell CJ, Stewart TG, Hernandez AF, Collins S, McCarthy MW, Jayaweera D, Gentile N, Castro M, Sulkowski M, McTigue K, Felker GM, Ginde AA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Thicklin F, Wilder R, Wilson S, Shenkman E, Naggie S; ACTIV-6 Study Group and Investigators. Boulware DR, et al. N Engl J Med. 2023 Sep 21;389(12):1085-1095. doi: 10.1056/NEJMoa2209421. N Engl J Med. 2023. PMID: 37733308 Free PMC article. Clinical Trial.
Advocating for mutually beneficial access to shelved compounds.
Pulley JM, Jerome RN, Shirey-Rice JK, Zaleski NM, Naylor HM, Pruijssers AJ, Jackson JC, Bernard GR, Holroyd KJ. Pulley JM, et al. Among authors: zaleski nm. Future Med Chem. 2018 Jun 1;10(12):1395-1398. doi: 10.4155/fmc-2018-0090. Epub 2018 May 23. Future Med Chem. 2018. PMID: 29788759 No abstract available.
Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.
Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS. Pulley JM, et al. Among authors: zaleski nm. Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1. Target Oncol. 2018. PMID: 29218624 Free PMC article. Review.
Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.
Pulley JM, Rhoads JP, Jerome RN, Challa AP, Erreger KB, Joly MM, Lavieri RR, Perry KE, Zaleski NM, Shirey-Rice JK, Aronoff DM. Pulley JM, et al. Among authors: zaleski nm. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:333-352. doi: 10.1146/annurev-pharmtox-010919-023537. Epub 2019 Jul 23. Annu Rev Pharmacol Toxicol. 2020. PMID: 31337270 Review.
Systematically Prioritizing Candidates in Genome-Based Drug Repurposing.
Challa AP, Lavieri RR, Lewis JT, Zaleski NM, Shirey-Rice JK, Harris PA, Aronoff DM, Pulley JM. Challa AP, et al. Among authors: zaleski nm. Assay Drug Dev Technol. 2019 Nov/Dec;17(8):352-363. doi: 10.1089/adt.2019.950. Epub 2019 Nov 26. Assay Drug Dev Technol. 2019. PMID: 31769998 Free PMC article.
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, Jayaweera D, Sulkowski M, Gentile N, Bramante C, Singh U, Dolor RJ, Ruiz-Unger J, Wilson S, DeLong A, Remaly A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Thicklin F, Hanna G, Ginde AA, Castro M, McTigue K, Shenkman E, Hernandez AF; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. McCarthy MW, et al. JAMA. 2023 Jan 24;329(4):296-305. doi: 10.1001/jama.2022.24100. JAMA. 2023. PMID: 36633838 Free PMC article.
Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases.
Challa AP, Zaleski NM, Jerome RN, Lavieri RR, Shirey-Rice JK, Barnado A, Lindsell CJ, Aronoff DM, Crofford LJ, Harris RC, Alp Ikizler T, Mayer IA, Holroyd KJ, Pulley JM. Challa AP, et al. Among authors: zaleski nm. Front Genet. 2021 Jul 28;12:707836. doi: 10.3389/fgene.2021.707836. eCollection 2021. Front Genet. 2021. PMID: 34394194 Free PMC article.
Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent Clostridioides difficile during COVID-19.
Lavieri RR, Dubberke ER, McGill SK, Bartelt L, Smith SA, Pandur BK, Phillips SE, Vermillion K, Shirey-Rice J, Pulley J, Xu Y, Lindsell CJ, Zaleski N, Jerome R, Doster RS, Aronoff DM. Lavieri RR, et al. Among authors: zaleski n. Anaerobe. 2023 Apr;80:102699. doi: 10.1016/j.anaerobe.2023.102699. Epub 2023 Jan 23. Anaerobe. 2023. PMID: 36702174 Free PMC article. Clinical Trial.
14 results